About InnFocus
InnFocus is a company based in Miami (United States) founded in 2003 was acquired by Santen Pharmaceuticals in July 2016. InnFocus has raised $49.4 million across 3 funding rounds from investors including HOYA, Santen Pharmaceuticals and Crown Venture Investment Fund. InnFocus operates in a competitive market with competitors including Glaukos, Myra Vision, Ivantis, Transcend Medical and Avisi Technologies, among others.
- Headquarter Miami, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$49.4 M (USD)
in 3 rounds
-
Latest Funding Round
$33.9 M (USD), Series C
Sep 30, 2015
-
Investors
HOYA
& 3 more
-
Employee Count
Not available
-
Acquired by
Santen Pharmaceuticals
(Jul 01, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of InnFocus
InnFocus has successfully raised a total of $49.4M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $33.9 million completed in September 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in InnFocus
InnFocus has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include HOYA, Santen Pharmaceuticals and Crown Venture Investment Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are targeted by family office-backed VC firm.
|
Locked | Locked | Locked | |
|
Direct secondary investments are made in private company shares.
|
Locked | Locked | Locked | |
|
Pharmaceutical products for ophthalmology and rheumatology diseases are manufactured.
|
Locked | Locked | Locked |
Investor details for InnFocus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by InnFocus
Investment portfolio details for InnFocus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - InnFocus
Detailed financials for InnFocus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Innfocus Comparisons
Peer comparison for InnFocus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of InnFocus
InnFocus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Glaukos, Myra Vision, Ivantis, Transcend Medical and Avisi Technologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of implants to treat glaucoma
|
|
| Locked | Locked | Locked |
Nanotechnology-based devices for glaucoma treatment are developed.
|
|
| Locked | Locked | Locked |
Implantable device to relieve intraocular pressure in open angle glaucoma
|
|
| Locked | Locked | Locked |
Minimally invasive glaucoma stents are developed to enhance aqueous outflow.
|
|
| Locked | Locked | Locked |
Nano-materials for glaucoma treatment implants are developed.
|
Detailed competitors of InnFocus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Innfocus
Complete news archive for InnFocus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InnFocus
InnFocus was founded in 2003 and raised its 1st funding round 8 years after it was founded.
InnFocus is headquartered in Miami, United States. It is registered at Miami, Florida, United States.
InnFocus is a funded company, having raised a total of $49.4M across 3 funding rounds to date.
InnFocus was established in 2003 in Miami, United States, with emphasis placed on biomaterials within the ophthalmology sector. An implantable MicroShunt device has been developed by the company to lower intraocular pressure as a glaucoma treatment option. Operations center on medical device innovation for eye care. The MicroShunt received CE Mark approval in 2012, enabling its use in relevant markets.
InnFocus's top competitors include Glaukos, Myra Vision and Avisi Technologies.
InnFocus has 4 investors. Key investors include HOYA, Santen Pharmaceuticals, Crown Venture Investment Fund, and Saints Capital.